Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EBITDA (2018 - 2025)

Historic EBITDA for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$3.1 million.

  • Exagen's EBITDA rose 3351.92% to -$3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.5 million, marking a year-over-year increase of 1897.4%. This contributed to the annual value of -$13.6 million for FY2024, which is 4028.99% up from last year.
  • According to the latest figures from Q3 2025, Exagen's EBITDA is -$3.1 million, which was up 3351.92% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Exagen's EBITDA ranged from a high of -$2.6 million in Q2 2024 and a low of -$14.5 million during Q4 2022
  • Over the past 5 years, Exagen's median EBITDA value was -$5.1 million (recorded in 2023), while the average stood at -$6.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 14493.21% in 2022, then surged by 6505.26% in 2023.
  • Over the past 5 years, Exagen's EBITDA (Quarter) stood at -$6.3 million in 2021, then crashed by 131.71% to -$14.5 million in 2022, then soared by 64.48% to -$5.1 million in 2023, then surged by 34.27% to -$3.4 million in 2024, then grew by 8.37% to -$3.1 million in 2025.
  • Its EBITDA stands at -$3.1 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$3.4 million for Q1 2025.